Chronic alcohol ingestion induces osteoclastogenesis and bone loss through IL-6 in mice

Jinlu Dai,1 Dinlii Lin,1 Jian Zhang,2 Paula Habib,1 Peter Smith,1 Jill Murtha,1,2 Zheng Fu,3 Zhi Yao,4 Yinghua Qi,5 and Evan T. Keller1,2,3,6,7

1Unit for Laboratory Animal Medicine,  
2Department of Pathology, and  
3Program in Immunology, University of Michigan, Ann Arbor, Michigan, USA,  
4Department of Immunology, Tianjin Medical University, Tianjin, China,  
5Laboratory of Cellular and Molecular Biology, Department of Internal Medicine, Tianjin 3rd Municipal Hospital, Tianjin, China  
6Institute of Gerontology, and  
7Program in Comparative Integrative Genomics, University of Michigan, Ann Arbor, Michigan, USA

Address correspondence to: Evan T. Keller, Room 5304 CCGCB Box 0940, 1500 E. Medical Center Drive, Ann Arbor, Michigan 48109-0940, USA. Phone: (734) 615-0280; Fax: (734) 936-9220; E-mail: etkeller@umich.edu.

Received for publication June 1, 2000, and accepted August 21, 2000.

To investigate the role of IL-6 in alcohol-mediated osteoporosis, we measured a variety of bone remodeling parameters in wild-type (il6+/+) or IL-6 gene knockout (il6−/−) mice that were fed either control or ethanol liquid diets for 4 months. In the il6−/− mice, ethanol ingestion decreased bone mineral density, as determined by dual-energy densitometry; decreased cancellous bone volume and trabecular width and increased trabecular spacing and osteoclast surface, as determined by histomorphometry of the femur; increased urinary deoxypyridinolines, as determined by ELISA; and increased CFU-GM formation and osteoclastogenesis as determined ex vivo in bone marrow cell cultures. In contrast, ethanol ingestion did not alter any of these parameters in the il6+/+ mice. Ethanol increased receptor activator of NF-κB ligand (RANKL) mRNA expression in the bone marrow of il6+/+ but not il6−/− mice. Additionally, ethanol decreased several osteoblastic parameters including osteoblast perimeter and osteoblast culture calcium retention in both il6+/+ and il6−/− mice. These findings demonstrate that ethanol induces bone loss through IL-6. Furthermore, they suggest that IL-6 achieves this effect by inducing RANKL and promoting CFU-GM formation and osteoclastogenesis.


Introduction
Alcohol (ethanol) abuse is a widespread clinical disorder that is accompanied by osteoporosis and increased incidence of fractures (1, 2). Up to 50% of ambulatory chronic alcoholics demonstrate radiographic evidence of extensive bone loss (3). Additionally, a negative correlation between ethanol intake and axial bone mineral density (BMD) in premenopausal (4) and postmenopausal (5, 6) women has been demonstrated.

The mechanisms through which ethanol promotes bone loss are currently not well understood. However, there is evidence that ethanol promotes osteoporosis through alteration of both the production and resorption arms of bone remodeling. For example, ethanol inhibits proliferation of human osteoblasts (7) and chick calvarial cells (8) in vitro. Additionally, ethanol increases bone resorption in chick tibiae (8) and rat trabecular bone (9). These latter observations suggest that an osteoclastic phase of bone loss contributes to ethanol-mediated osteoporosis.

IL-6, a multifunctional cytokine produced by a great diversity of cells, is recognized as an important regulator of the immune and hematopoietic systems (reviewed in ref. 10). IL-6 has joined ranks with other cytokines/growth factors such as IL-1α, IL-1β, and TNF-α as being an important contributor to the process of bone resorption (reviewed in ref. 11). Although several studies could not document an influence of IL-6 on bone (12–15), the bulk of research supports IL-6’s role in bone resorption (reviewed in ref. 16).

On the basis of the reports that demonstrate IL-6’s ability to induce osteoclastogenesis and bone loss, and the observation that ethanol induces IL-6 gene expression in a bone marrow stromal cell line (17), we have hypothesized that ethanol induces bone loss through its ability to induce IL-6-mediated osteoclastogenesis. To test this hypothesis, we have performed in vitro and in vivo studies to determine whether IL-6–deficient mice (il6−/−) are protected from ethanol-induced bone loss. In addition, we have investigated whether ethanol-induced bone loss is linked to osteoclastogenesis.

Methods
Animals. Male 8-week-old C57/BL6 mice (il6+/+) or il6−/− backcrossed on a C57/BL6 background (18) for eight generations were individually housed in plastic cages...
under standard laboratory animal conditions. Mice were fed the National Research Council (NRC) liquid diet (19), which contains 100% of the vitamin and mineral requirements set by the NRC. The ethanol-treated group diet contained 26% of energy as ethanol, 31.5% as carbohydrates, 12.5% as protein, and 30% as fat (diet no. 710279; Dyets, Bethlehem, Pennsylvania, USA) as described previously (20), resulting in a dietary ethanol concentration of 5% (vol/vol) and blood ethanol concentrations of 9.9 and 7.3 mmol/l at 5 and 20 hours after feeding, respectively (19). An isocaloric level of maltose was substituted for ethanol in the nonethanol control diet. Diets were prepared fresh daily. To minimize differences due to food intake, mice were pair fed. To accomplish this, food intake for each ethanol-fed mouse was measured, then its respective pair-fed control diet-fed mouse received the same volume of food the following day. Animals were fed for 4 months and were then sacrificed by CO₂ asphyxiation. Liver was collected and stored in formalin for standard histopathological evaluation. All outcome measurements were performed on individual mouse samples, i.e., there was no pooling of samples. The University of Michigan Animal Care and Use Committee approved the animal protocols.

**Bone densitometry.** BMD was measured using dual-energy x-ray absorptiometry (DEXA) on an Eclipse peripheral DEXA Scanner using pDEXA Sabre software, version 3.9.4 in research mode (Norland Medical Systems, Fort Atkinson, Wisconsin, USA). To measure whole-body BMD, mice were anesthetized with ketamine before and after ethanol feeding and were placed in sternal recumbency on the scanner. The mice were scanned at 10 mm/s with a resolution of 0.5 mm × 0.5 mm. BMD was determined in a window that excluded the calvarium and tail. To measure femoral BMD, the right femur was excised from soft tissue and placed on the scanner in lateral position. The femur was scanned at 5 mm/s with a resolution of 0.1 mm × 0.1 mm. BMD was determined in a window that encompassed the entire femur. Short-term BMD precision (percent coefficient of variation) was approximately 3% for both of these techniques.

**Quantification of deoxypyridinolines.** At the time of sacrifice, urine was collected and frozen at −80°C until assayed. Urine creatinine was measured using a creatinine kit (Metra Biosystems, Mountain View, California, USA) as recommended by the manufacturer. Deoxypyridinolines (Dpd's) were measured using the Pyrilinks-D kit (Metra Biosystems) as recommended by the manufacturer. A standard curve was created using a four-parameter fit generated by MetraFIT software (Metra Biosystems). Dpd was corrected for variations in urine concentration by dividing the Dpd value (nmol/l) by the creatinine value (mmol/l) for each sample.

**Quantification of IL-6, estradiol, testosterone, and ethanol.** Serum samples were collected before treatment using retro-orbital venipuncture, and, after treatment, using cardiac puncture. Samples were measured immediately for ethanol levels and frozen at −80°C until assayed for IL-6, estrogen, and testosterone. IL-6 was measured using a murine ELISA kit (Murine IL-6 Quantikine kit; R&D Systems, Minneapolis, Minnesota, USA) as recommended by the manufacturer. Ethanol levels were determined by the measuring the ability of alcohol dehydrogenase to form acetaldehyde from the blood sample as recommended by the manufacturer (Alcohol Level Kit; Sigma Chemical Co., St. Louis, Missouri, USA). Estradiol levels were measured using ELISA (17β-Estradiol ELISA; KMI Diagnostics, Minneapolis, Minnesota, USA) as recommended by the manufacturer. Total testosterone levels were measured by RIA (Testosterone RIA kit; Diagnostic Systems Laboratories Inc., Webster, Texas, USA).

**Quantification of CFU-fibroblast and CFU-osteoblast and culture calcium retention.** CFU-fibroblasts (CFU-Fs) and CFU-osteoblasts (CFU-OBs) were measured as reported previously (21), with minor modification. Briefly, mouse femora were flushed with 3 ml of phenol red-free α-MEM to obtain marrow cells. The cells were rinsed twice, total cell numbers per femur determined and resuspended to obtain a single-cell suspension of 1 × 10⁶ cells/ml. For determination of CFU-Fs, 1.5 × 10⁶ (150 μl) cells were seeded into 4 ml of complete media (α-MEM, 15% FBS, 50 μg/ml ascorbic acid, 10 mM β-glycerophosphate) + 10 nM dexamethasone per well of six-well plate. Assays were performed in duplicate for each animal. One half of the media was removed and replaced on day 5 with α-MEM, containing 30% FBS, 100 μg/ml ascorbic acid, 20 mM β-glycerophosphate to result in a final concentration of the original complete media. Dexamethasone was not added after the initial culture period. On day 10 of culture, cells were fixed stained for alkaline phosphatase (ALP) and counter stained with hematoxylin. ALP-positive colonies containing ≥20 cells were enumerated. To determine CFU-OB, cultures were established in duplicate and maintained as for CFU-Fs except 2.5 × 10⁶ cells (250 μl of 1 × 10⁶ cells/ml) were plated per well. Media were replaced every 5 days as already described here. Cells were cultured for 25 day at which time they were fixed in 18% formaldehyde, 50% ethanol, 32% deionized water for 1 minute, and then stained using Von Kossa’s method. Stained colonies were enumerated. To measure calcium content in cultures, cells were prepared and grown as for CFU-OB; then calcium content was measured using standard biochemistry (Calcium Kit, Fisher Scientific Co., Pittsburgh, Pennsylvania, USA).

**Quantification of osteoclast formation in bone marrow cultures.** Osteoclast formation was determined as reported previously (21), with minor modifications. Briefly, marrow cells were collected as already described here. To determine osteoclast number, the cells were plated at 1.5 × 10⁶ cells per 2 cm² well on a 13 mm² round tissue culture cover slips (four to six replicate cultures per mouse). The cultures were maintained for 9 days in the presence of 10⁻⁶ M 1,25(OH)₂D₃ with replacement of half the medium every 3 days. To confirm the identification of osteoclasts, several replicates were evaluated for tartrate-
resistant acid phosphatase (TRAP) (Acid Phosphatase Kit; Sigma Chemical Co.) and calcitonin receptors (CTRs) by a method described previously (22) using [125I]salmon calcitonin. Results are reported as number of multinucleated (more than three nuclei) TRAP-positive cells and CTR-positive cells per cover slip.

Assessment of individual CFU-F colonies for ability to support osteoclast formation. CFU-F osteoclastogenic activity was determined as reported previously (21), with minor modifications. Briefly, 100 µl of 2 × 10^6 bone marrow cells/ml in α-MEM was placed into wells of 96-well plates containing 100 µl of α-MEM, 30% FBS, 100 µg/ml ascorbic acid, and 20 mM β-glycerophosphate in each well of 96-well plate. The bone marrow cells were incubated for 5 days, at which time spleen cells (for a source of osteoclastogenic precursors) were isolated from il6^−/− mice and resuspended to 1 × 10^6/ml in α-MEM with 20% FBS and 20 nM vitamin D3. Then 100 µl of media was removed from each well, and 100 µl of the spleen cell suspension was added. On day 9, one half of the media was removed and replaced with α-MEM with 20% FBS and 20 nM VitD3. On day 13, the cells were stained for TRAP, and each well was examined microscopically for the presence of CFU-Fs (20 cells) and osteoclastic cells (TRAP-positive).

Quantification of CFU-GMs. To determine CFU-GM formation, 1.25 × 10^5 of the bone marrow cells (i.e., 250 µl of 5 × 10^5 cells/ml) were seeded into 2.5 ml of a methylcellulose-based media containing CFU-GM–promoting growth factors (MethoCult HCC-3534; Stem Cell Technologies, Vancouver, British Columbia, Canada) in a 15-ml sterile test tube. The cells were vortexed and bubbles allowed to settle. Then 1.1 ml per media mixture was placed into a 35-mm cell culture dish using a 16 gauge 1.5-inch needle. Assays were performed in duplicate. The duplicate 35-mm dishes with cells were placed into a 150-mm plate along with a covered 35-mm dish filled with 3 ml of sterile water. The cells were incubated at 37°C 5% CO2 for 7 days, at which time CFU-GMs (defined as >50 cells) were counted.

Evaluation of receptor activator of NF-κB ligand mRNA levels. Bone marrow cells were frozen at −80°C until total RNA was collected using Trizol reagent (Life Technologies, Grand Island, New York, USA) as recommended by the manufacturer. PCR primers used for the detection of receptor activator of NF-κB ligand (RANKL), based on published sequence (23), consisted of upper primer: 5′CCATCGGGTTCCCATAAAGTCAC3′ and lower primer: 5′AAAGCCCAAAAGTAGCTCGCATCT3′, resulting in a PCR product of 407 bp. Murine β-actin mRNA expression was used as an internal control. The β-actin primers consisted of upper primer: 5′GGGGCCGTCCTAGGCAACAA3′ and lower primer: 5′CTCTTTGTAGTGCACCCAGATTTTC3′, resulting in a PCR product of 540 bp. RT-PCR was performed with 1 µg of total RNA using the Access RT-PCR system (Promega Corp., Madison, Wisconsin, USA), as directed by the manufacturer, in a thermal cycler (GeneAmp PCR system 9700; Perkin-Elmer Applied Biosystems, Norwalk, Connecticut, USA) under the following conditions: first strand cDNA was synthesized at 48°C for 45 minutes and then denatured at 94°C for 2 minutes for the first cycle and at 15 seconds for additional cycles; annealing was performed at 55°C for 30 seconds and extension at 72°C for 60 seconds. Final extension was at 72°C for 5 minutes. To enable semiquantitation, 30 cycles of amplification were performed, which was in the log-linear range of amplification for RANKL. The PCR products were subjected to electrophoresis on a 1.5% agarose gel, stained with ethidium bromide, and band density measured by densitometry. The density of the RANKL PCR product band was divided by the density of the β-actin PCR product band for each sample.

Bone histomorphometry. The right femur was dissected from soft tissue, fixed in 10% phosphate-buffered formalin for 24 hours, decalcified in 14% EDTA, and embedded in a lateral position in paraffin. Longitudinal sections (5-µM thick) from the middle of the femur were stained with hematoxylin and eosin or trichrome stain. Histomorphometry was performed using Bioquant Nova Imaging Software (Bioquant, Nashville, Tennessee, USA) and digitizer tablet (Summagraphics Corp., Seymour, Connecticut, USA). Histomorphometric parameters of the secondary spongiosa in the distal femoral metaphysis were measured in standard rectangular area (1.5 mm²) at least 0.2 mm proximal to the distal femoral growth plate, to exclude primary spongiosa (24). Parameters were measured at a magnification of 100. The terminology used was that recommended by the Histomorphometry Nomenclature Committee of the American Society for Bone and Mineral Research (25).

Statistics. Repeated measures ANCOVA was used to test for significant differences in mean BMD among groups, using weight as a covariate. Repeated measure ANOVA was used to test for significant differences between pre- and post-treatment IL-6 levels. Factorial ANOVA was used to test for significant differences in parameters, other than BMD or IL-6, among groups. Fisher’s least significant difference was used for post hoc analysis. Statistical significance was determined as P < 0.05.

Results
Il6^−/− and il6^−/− 6-month-old male mice on a C57Bl/6 background were pair fed 5% ethanol or maltose-control liquid diets for 4 months. Blood ethanol levels, 4 hours after an individual feeding, were 9.6 ± 2.5 mMol/l in ethanol-fed mice compared to 0.23 ± 1.2 mMol/l in control-fed mice (P < 0.001) at 4 months after initiation of diet. The levels present in the ethanol-fed mice represent the blood levels obtained in chronic alcoholic patients (26, 27).

At the end of the study period, mice were sacrificed and evaluated for a variety of parameters. To rule out hepatic inflammation or cirrhosis, common sequelae to chronic ethanol ingestion, the liver was evaluated for pathological changes. There was no evidence...
of gross or histological liver pathology in any animal. Ethanol has been reported to modulate gonadal hormone levels (28, 29), which in turn can modify bone remodeling. Therefore, we evaluated serum estradiol and testosterone levels. Both estradiol and testosterone levels were similar among all groups of animals (ANOVA; data not shown). To confirm that ethanol induced IL-6 expression in vivo, we measured serum IL-6 levels before initiation of ethanol feeding and at the end of the study. Serum IL-6 levels were nondetectable (ELISA sensitivity = 3 pg/ml) in all the il6+/+ mice before the initiation of ethanol feeding. At the end of the study, serum IL-6 levels were below the ELISA nondetectable in the control-fed il6+/+ mice; whereas they were 33.6 ± 5.3 pg/ml in the ethanol-fed il6+/+ mice. For statistical analysis, we substituted the minimal detectable level of 3 pg/ml (which is more conservative than placing 0 pg/ml) for mice with undetectable IL-6 levels. There was a significant increase (P < 0.001, repeated measures ANOVA) in IL-6 levels in the ethanol-fed mice. Taken together, these data demonstrate that ethanol ingestion induces IL-6 expression in the absence of liver pathology and independent of modulating estradiol or testosterone levels.

To determine whether ethanol induces bone loss in mice, BMD was measured using DEXA. Whole-body BMD before and after ethanol treatment, and post-ethanol treatment BMD of the excised right femur were quantified. The whole-body BMD decreased by 3.01 ± 1.0 % in the ethanol-fed il6+/+ mice compared with the control-fed il6+/+ mice (Figure 1a). However, there was no decrease in the ethanol-fed il6+/− mice compared with the control-fed il6+/− mice (Figure 1a). Consistent with these findings, femoral BMD decreased by 5.37 ± 1.93 % in the ethanol-fed il6+/+ mice compared with the control-fed il6+/+ mice (Figure 1b). In contrast, there was no significant decrease of BMD in the ethanol-fed il6+/− mice but the Dpd levels were similar in the ethanol-fed and control-fed il6+/− mice (Figure 1b). To support the BMD findings further, urinary Dpd level, an indicator of bone resorption, was quantified. In agreement with the BMD data, Dpd levels were mildly elevated in the ethanol-fed compared with the control-fed il6+/+ mice, but the Dpd levels were similar in the ethanol-fed and control-fed il6+/− mice (Figure 2). These data establish that IL-6 is required for ethanol to induce bone loss. Furthermore, the increased Dpd levels suggest that increased bone resorption is a component of the IL-6–mediated activity.

IL-6 induces osteoclastogenesis (30); thus, if ethanol requires IL-6 to induce bone loss, ethanol may promote bone loss through induction of osteoclastogenesis.
evaluate this hypothesis, we determined the effect of ethanol ingestion on formation of bone marrow CFU-GMs, which are the osteoclast precursors. CFU-GMs were increased approximately 40% in ethanol-fed il6+/+ animals (Figure 3a). In contrast, ethanol ingestion did not increase CFU-GMs in il6–/– mice (Figure 3a). In parallel studies, the effect of ethanol ingestion and the requirement of IL-6 on formation of osteoclast-like cells was examined in bone marrow cell cultures. Similar to findings for CFU-GMs, ethanol-fed il6+/+ mice exhibited approximately a 45% increase of osteoclast-like cells (Figure 3b). This increase was not observed in bone marrow from the il6–/– mice (Figure 3b). To ensure the increases of CFU-GMs and osteoclast-like cells were not due to a general increase in bone marrow cell number, we determined the number of cells obtained per femur. There was an average of 2.2 ± 0.73 × 10⁷ cells per femur, and no differences were detected among the groups (data not shown). Taken together, these data suggest that ethanol induces CFU-GM formation, resulting in osteoclastogenesis through IL-6. In turn, IL-6 is known to induce RANKL expression (31, 32), which induces osteoclastogenesis through binding to RANK on the cell membrane of osteoclastogenic precursors (33, 34). Thus, it follows that ethanol may also promote osteoclastogenesis through IL-6–induced RANKL expression. Accordingly, we semiquantitated RANKL mRNA expression in the bone marrow of the mice. Ethanol ingestion induced approximately a 70% increase of RANKL mRNA expression in the il6+/+ animals (Figure 3c). In contrast, ethanol ingestion did not increase RANKL mRNA expression in il6–/– mice (Figure 3c). These data are consistent with IL-6’s ability to induce RANKL expression and osteoclastogenesis.

To assess further the effect of ethanol on the capability of the bone marrow microenvironment to support osteoclastogenesis, we determined the ability of CFU-Fs from il6+/+ and il6–/– ethanol-fed or control-diet–fed mice to induce osteoclast-like cells in single-cell suspensions of spleen cells from il6+/+ mice (which serve as
cell suspension from spleens of animals, were established in 96-well plates for 5-days; then single-row was collected from the femur. CFU-F cultures, from individual ethanol diet for 4 months. The mice were then killed, and bone marrow was overlayed with splenic cells from normally fed mice as a source of normal osteoclast precursors. Specifically, bone marrow cells isolated from il6+/+ and il6–/– mice were added to the wells. The cells were maintained for an additional 8 days and then stained for TRAP. Each well was then examined microscopically for the presence of CFU-F (>20 cells) and osteoclast-like cells (TRAP-positive). Data are presented as mean (± SD) CFU-F with osteoclasts.

Discussion

Although the ability of ethanol to induce osteopenia has been recognized for decades, the mechanism through which this occurs has not been elucidated. The results from the present study demonstrate that chronic ethanol ingestion increases osteoclastogenesis and bone loss through IL-6 in mice. These findings are consistent with the observation that ethanol induces bone resorption in chick tibiae (8) and rat trabecular bone (9). Furthermore, these findings are in line with the evidence that IL-6 mediates osteoclastogenesis and bone loss in estrogen- and androgen-deficient states (30, 35). Additionally, they clarify the cellular changes underlying the increased bone resorption associated with ethanol ingestion. Taken together with our current observation that ethanol induces IL-6 expression in vivo and earlier observa-

Table 1
Static histomorphometry of distal femoral cancellous bone in il6+/+ and il6–/– mice fed a control or ethanol liquid diet for 4 months

<table>
<thead>
<tr>
<th></th>
<th>il6+/+</th>
<th>il6–/–</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Control</td>
<td>Ethanol</td>
</tr>
<tr>
<td>Cancellous bone area (%)</td>
<td>28.7 ± 0.9</td>
<td>22.6 ± 0.6</td>
</tr>
<tr>
<td>Osteoclast perimeter (%)</td>
<td>2.3 ± 0.2</td>
<td>3.6 ± 0.3</td>
</tr>
<tr>
<td>Osteoblast perimeter (%)</td>
<td>3.6 ± 0.5</td>
<td>2.6 ± 0.6</td>
</tr>
<tr>
<td>Trabecular number (mm–1)</td>
<td>3.0 ± 0.5</td>
<td>3.2 ± 0.5</td>
</tr>
<tr>
<td>Trabecular width (µM)</td>
<td>48.6 ± 1.8</td>
<td>39.4 ± 0.7</td>
</tr>
<tr>
<td>Trabecular spacing (µM)</td>
<td>439.0 ± 13.3</td>
<td>363 ± 16.7</td>
</tr>
</tbody>
</table>

Data are presented as mean ± SEM. n = 6 mice per group. *P < 0.01 versus il6+/+ control-diet-fed mice. **P < 0.01 versus il6–/– control-diet-fed mice.
tions that IL-6 induces bone loss through osteoclastogenesis (30), it appears that IL-6 mediates the effects of ethanol on bone loss in this murine model.

The role of bone resorption in ethanol-induced bone loss has not previously been well documented. Taken together, our data demonstrate that ethanol induces bone resorption. The modest increase of urinary Dpd levels induced by ethanol is only suggestive that ethanol induces bone resorption. This observation is consistent with the finding of increased urinary excretion of hydroxyproline in chronic alcoholic patients (36). Stronger evidence that ethanol induces osteoclastogenic activity was provided by the observation of increased osteoclastogenesis in bone marrow cell cultures and the bone histomorphometry finding of increased osteoclast perimeter in the ethanol-fed il6+/+ mice. These results are consistent with histomorphometric measurements by Diez et al. (37) and Johnell et al. (38) who observed increased resorptive surface and osteoclast number in alcoholic men. However, our data contrast with those of Crilly et al. (39), who did not observe a change in osteoclastic parameters in alcoholic men. Differences in patient populations (e.g., age and duration of ethanol abuse) are likely to account for the discrepancies between these earlier reports. Our data cannot conclusively delineate whether increased bone resorption or decreased bone production is the major mediator of ethanol-induced bone loss, because both increased resorptive parameters and decreased osteoblast function were observed in the ethanol-fed mice.

Hepatitis and hepatic cirrhosis are common sequelae of chronic ethanol abuse. This nidus of inflammation may lead to general overexpression of inflammatory cytokines and malnutrition that promote bone resorption. To minimize confounding from hepatic disease, we fed the mice for a period that would not induce cirrhosis. The absence of hepatic inflammation and cirrhosis was confirmed by histology; however, bone loss was observed. This observation is consistent with previous reports in humans that demonstrate bone loss in the absence of cirrhosis (37, 40). These results demonstrate that ethanol induces bone loss through a mechanism other than nonspecific hepatic inflammation.

The observations that ethanol decreased (a) total BMD, (b) femoral BMD, and (c) cancellous bone area and increased (a) osteoclast perimeter and (b) osteoclast number in marrow cultures from the il6+/+ but not the il6–/– mice unequivocally demonstrates that ethanol requires IL-6 to induce bone loss in mice. These data are consistent with IL-6’s ability to promote bone resorption through stimulating osteoclastogenesis (12, 41–43). Furthermore, these results parallel those of Poli et al. (44) and Bellido et al. (35), who demonstrated that IL-6−/− deficient mice are protected from gonadectomy-induced osteopenia. However, results derived from il6–/– mice must be interpreted with the caveat that they may have bone modeling defects and remodeling defects and thus their mature skeleton may not be directly comparable to that of the

**Figure 5**

Effect of ethanol ingestion on osteoblast parameters in wild-type or IL-6 gene knockout mice. Il6+/+ or il6–/– mice were fed either a control diet or 5% ethanol diet for 4 months. The mice were then killed and bone marrow was collected from the femur. CFU-F, CFU-OB, and Ca. (a) To assess the marrow’s ability to support osteoblastogenesis, marrow cultures were maintained for 10 days in the presence of 50 μg/ml ascorbic acid and 10 mM β-glycerophosphate. CFU-Fs were determined by counting ALP-positive colonies as described in Methods. (b) To assess for the marrow’s ability to support osteoblast function, marrow cultures were maintained for 25 days in the presence of 50 μg/ml ascorbic acid and 10 mM β-glycerophosphate. (b) CFU-OBs were determined by counting von Kossa-positive colonies and (c) total calcium in the cultures was determined as described in Methods. Data are reported as mean (± SD). Data were analyzed using ANOVA and Fisher’s least significant difference for post hoc analysis. *P < 0.01 compared with control-fed il6–/– mice. **P = 0.02 compared with control-fed il6–/– mice. "P = 0.005 compared with control-fed il6–/– mice. Measurements were performed on ten individual mice per group.
Ethanol-induced bone loss and increased osteoclastogenesis were associated with increased CFU-GM formation in the il6+/+ mice. However, ethanol did not induce bone loss, osteoclastogenesis or CFU-GM in the il6−/− mice. These findings, taken together with previous studies that demonstrate IL-6 induces CFU-GMs (30, 45–47), suggest that ethanol promotes bone loss, in part, through IL-6-mediated induction of CFU-GM, which in turns leads to osteoclastogenesis. However, the observation that ethanol did not modify the ability of CFU-Fs to support osteoclastogenesis in the il6−/− mice suggests that ethanol mediates osteoclastogenesis through some factor independent of stromal support. The observation that ethanol induced RANKL mRNA in bone marrow cells from the il6+/+ mice but not the il6−/− mice suggests that RANKL mediates the IL-6 effect of ethanol on bone loss. This finding is consistent with the previous report the IL-6 stimulates RANKL production in human and murine bone marrow (31, 32).

In addition to increasing bone resorption, ethanol ingestion reduced indices of osteoblast function. These findings are consistent with previous reports that bone histomorphometric indices of osteoblastic activity (2) and osteocalcin levels (2, 48, 49) are decreased in chronic alcoholic patients. At the cellular level, ethanol has been shown to inhibit proliferation of rat osteosarcoma cells (50) and human osteoblast-like cells (51, 52) in vitro, which is consistent with our observation of decreased CFU-OB formation in the ethanol-fed il6+/+ mice. Additionally, ethanol and its metabolite, acetaldehyde, have been shown to inhibit CFU-F formation, the osteoblast precursors, in vitro (52). However, the ethanol-fed mice in the current study did not demonstrate decreased CFU-F formation. These findings are in agreement with reports that ethanol does not modulate osteoblastic cell number (53) or requires very high concentrations to do so (54). Differences in ethanol metabolism in vivo versus in vitro, dosage of ethanol, or duration of exposure may account for these discrepancies. Ethanol ingestion decreased the amount of calcium retained in the cultures, suggesting that it inhibits osteoblast function. In the current report, ethanol’s decrease of osteoblast surface area and cell culture calcium retention was similar in both the il6+/+ and il6−/− mice. These data suggest that ethanol represses osteoblast function independently of IL-6.

In conclusion, deletion of the IL-6 gene protected mice from ethanol-induced bone loss. Furthermore, the absence of IL-6 diminished the ability of ethanol to induce CFU-GM, osteoclast-like cells, RANKL mRNA, and trabecular-associated osteoclasts. Thus, there appears to be an absolute requirement for IL-6 to induce ethanol-mediated osteoclastogenesis and bone loss. These results, together with the current evidence that ethanol induces serum IL-6 expression in il6+/+ mice and the previous observation that ethanol activates the IL-6 gene promoter in bone marrow stromal cells (17), suggest the following mechanism for the pathophysiomy of ethanol-induced osteopenia. Ethanol, independent of modulation of gonadal hormones, induces the IL-6 promoter, either directly or indirectly, resulting in increased IL-6 expression. IL-6, in turn, promotes CFU-GM formation and RANKL expression, resulting in osteoclastogenesis and bone resorption. The relative contribution of increased osteoclastogenesis or decreased osteoblast activity to ethanol-induced bone loss remains unknown, but deserves further study.

Acknowledgments
We thank R. Murray for providing the il6−/− mice. This work was supported by NIH grant R01 AG-15904.

10. Ersberger, W.B., and Keller, E.T. 2000. Age-associated increased IL-6 gene expression, resulting in osteoclastogenesis and bone resorption. In conclusion, deletion of the IL-6 gene protected mice from ethanol-induced bone loss. Furthermore, the absence of IL-6 diminished the ability of ethanol to induce CFU-GM, osteoclast-like cells, RANKL mRNA, and trabecular-associated osteoclasts. Thus, there appears to be an absolute requirement for IL-6 to induce ethanol-mediated osteoclastogenesis and bone loss. These results, together with the current evidence that ethanol induces serum IL-6 expression in il6+/+ mice and the previous observation that ethanol activates the IL-6 gene promoter in bone marrow stromal cells (17), suggest the following mechanism for the pathophysiomy of ethanol-induced osteopenia. Ethanol, independent of modulation of gonadal hormones, induces the IL-6 promoter, either directly or indirectly, resulting in increased IL-6 expression. IL-6, in turn, promotes CFU-GM formation and RANKL expression, resulting in osteoclastogenesis and bone resorption. The relative contribution of increased osteoclastogenesis or decreased osteoblast activity to ethanol-induced bone loss remains unknown, but deserves further study.

Acknowledgments
We thank R. Murray for providing the il6−/− mice. This work was supported by NIH grant R01 AG-15904.